|
| Neurotune wins Award |
| Neurotune wins ZKB Pioneer Award TECHNOPARK 2007 |
|
|
 |
 |
|
Neurotune, based in Schlieren (Zurich), Switzerland, was incorporated in January 2005 as a spin-off from Prionics AG.
Neurotune develops small-molecular drugs to treat disorders of the human peripheral and central nervous system, as well as drugs to treat age-related muscle atrophy – Sarcopenia.
The enormous economic potential of novel drugs for the treatment of central nervous system disorders lays ground for a successful development of the company.
The scope of activities at Neurotune is
 |
drug development from preclinical R&D up to clinical Phase II |
|
out-licensing at the stage of clinical Phase II |
|
in-licensing of drug candidates |
Our core competences lie in
|
biochemistry, neurological disorders of the central and peripheral
nervous system |
|
medicinal chemistry on small molecular drugs |
|
|
© Copyright by Neurotune Switzerland |
|
